Groups

Fund universe
View all funds
Groups A-Z
Group name
Fund universe
View funds in this group

News & Research

PIMCO

Chequebooks at the ready: Biotech is on the shopping list

Jo Groves
26 November 2025
This is a sector where active strategies offer a real advantage

Five funds for investors who are bullish on equity markets

Patrick Sanders
26 November 2025
Shard Capital’s Ernst Knacke highlights his highest-conviction active funds worldwide.

The only reason emerging markets lagged for 15 years – and why that headwind is turning

Matteo Anelli
25 November 2025
NinetyOne’s Varun Laijawalla says dilution explains emerging markets’ long underperformance.

‘Don’t fall in love with stocks’: Invesco's Walker on discipline, sell signals and UK sentiment

Matteo Anelli
24 November 2025
Scepticism and a robust process matter more than conviction.

UK equities: A low-bar opportunity hiding in plain sight

24 November 2025

The UK funds outperforming over all standard timeframes

24 November 2025

Murray International Trust: ‘Don’t quibble over price’

21 November 2025

Fundswire

The Diverse income Trust: the benefits of diversification

Premier Miton
24 November 2025
Read more

Merlin Weekly Macro: Reeves in a budget bind

Jupiter Asset Management
24 November 2025
Read more

Artemis Strategic Bond Fund quarterly commentary

Artemis Fund Managers
24 November 2025
Read more

A turning point for healthcare policy and sentiment

Polar Capital
22 November 2025
Read more

The three key catalysts for healthcare

Polar Capital
22 November 2025
Read more

Performance Tables

Contact Details

DWS Investments UK Limited, Winchester House, 1 Great Winchester Street, London, EC2N 2DB

44 (0)20 7547 1747

etf.dws.com

Xtrackers@dws.com

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.